Advanced Circulatory, makers of medical devices providing Intrathoracic Pressure Regulation (IPR) Therapy, will continue to work with the U.S. Food and Drug Administration (FDA) on a pathway to premarket approval (PMA) for the company’s ResQCPR System, based on recommendations from the FDA Circulatory System Devices Advisory Panel meeting on May 6.
